A detailed history of Atlas Private Wealth Management transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Atlas Private Wealth Management holds 4,537 shares of BMY stock, worth $267,093. This represents 0.11% of its overall portfolio holdings.

Number of Shares
4,537
Previous 4,527 0.22%
Holding current value
$267,093
Previous $232,000 6.03%
% of portfolio
0.11%
Previous 0.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

BUY
$47.98 - $54.4 $479 - $544
10 Added 0.22%
4,537 $246,000
Q2 2023

Jul 13, 2023

SELL
$63.71 - $70.74 $65,430 - $72,649
-1,027 Reduced 18.49%
4,527 $289,000
Q1 2023

Apr 26, 2023

BUY
$65.71 - $74.53 $42,711 - $48,444
650 Added 13.25%
5,554 $384,000
Q3 2022

Oct 26, 2022

SELL
$0.13 - $76.84 $39 - $23,052
-300 Reduced 5.76%
4,904 $349,000
Q1 2022

Apr 25, 2022

BUY
$61.48 - $73.72 $12,787 - $15,333
208 Added 4.16%
5,204 $380,000
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $267,935 - $312,349
4,996 New
4,996 $312,000
Q2 2021

Aug 05, 2021

SELL
$61.91 - $67.42 $30,955 - $33,710
-500 Closed
0 $0
Q4 2020

Jan 27, 2021

SELL
$57.74 - $65.43 $5,774 - $6,543
-100 Reduced 16.67%
500 $31,000
Q3 2020

Nov 05, 2020

SELL
$57.43 - $63.64 $34,458 - $38,184
-600 Reduced 50.0%
600 $36,000
Q2 2020

Aug 04, 2020

SELL
$54.82 - $64.09 $10,854 - $12,689
-198 Reduced 14.16%
1,200 $71,000
Q1 2020

May 12, 2020

BUY
$46.4 - $67.43 $139 - $202
3 Added 0.22%
1,398 $77,000
Q4 2019

Feb 11, 2020

BUY
$49.21 - $64.19 $68,647 - $89,545
1,395 New
1,395 $90,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Atlas Private Wealth Management Portfolio

Follow Atlas Private Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlas Private Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Atlas Private Wealth Management with notifications on news.